



Administration of Meningococcal ACWY conjugate vaccine

Patient group direction (PGD) template

Publication date: 01 July 2025

PGD No: 2025/2835

Expiry date: 30 June 2028



Translations



Easy read



BSL



Audio



Large print



Braille

Translations and other formats are available on request at:

 p hs.otherformats@p hs.scot

Public Health Scotland is Scotland's national agency for improving and protecting the health and wellbeing of Scotland's people.

© Public Health Scotland 2025



This publication is licensed for re-use under the [Open Government Licence v3.0](#).

For more information, visit
www.publichealthscotland.scot/ogl

www.publichealthscotland.scot

Most recent changes

Version	Date	Summary of changes
7.0	1 July 2025	<p>The following changes to version 6.3 of the PGD have been made:</p> <ul style="list-style-type: none"> • Inclusion criteria updated in relation to individuals requiring vaccination for the prevention of secondary cases of Meningitis ACWY • Exclusion added in relation to those that have previously received MenACWY conjugate vaccine from 10 years of age • Exclusion section, latex allergy wording updated • Section 1.4 Coadministration with other vaccines updated to reflect interval guidance in relation to Hib/MenC and MenACWY vaccination • Section 1.5 Action if excluded updated in relation to individuals who have received MenACWY conjugate vaccine over 1 year of age and in the last 12 months • Section 2.2 Route of Administration, subcutaneous off licence wording updated to align with Chapter 4 of the Green Book. • Section 2.4 Frequency for individuals with underlying medical conditions updated to reflect Green Book Chapter 7 guidance and changes to routine childhood immunisation programme from 01 July 2025 • Section 2.10. Is the use outwith the SmPC? Information added in relation to off-label use and consent process, consider, as part of the consent process • Section 2.12 Additional Information, information added on: vaccine administration in relation to commencement of immunosuppressive treatment • Changes to the childhood immunisation programme from 1 July 2025 and discontinuation of Menitorix® (Hib/MenC) • Section 3.3 Advice to patient or carer updated to include advice in relation to protection only conferred against groups A, C, W and Y • Section 4.1 updated to include pharmacy technicians

Contents

Most recent changes	1
Authorisation	3
1. Clinical situation	4
2. Description of treatment	8
3. Adverse reactions	14
4. Characteristics of staff authorised under the PGD	17
5. Audit trail	19
6. Additional references	20
7. PGD for administration of Meningococcal ACWY conjugate vaccine V7.0 (valid from 01 July 2025 and expires 30 June 2028): authorisation	21
8. Version history	23

Authorisation



PGD Meningococcal ACWY conjugate vaccine

This specimen Patient Group Direction (PGD) template has been produced by Public Health Scotland to assist NHS Boards. NHS Boards should ensure that the final PGD is considered and approved in line with local clinical governance arrangements for PGDs.

The qualified health professionals who may administer meningococcal ACWY conjugate under this PGD can only do so as named individuals. It is the responsibility of each professional to practice within the bounds of their own competence and in accordance with their own Code of Professional Conduct and to ensure familiarity with the manufacturer's product information/Summary of Product Characteristics (SmPC) for all vaccines administered in accordance with this PGD.

NHS Board governance arrangements will indicate how records of staff authorised to operate this PGD will be maintained. Under PGD legislation there can be no delegation. Administration of the vaccine has to be by the same practitioner who has assessed the patient under the PGD.




This PGD has been produced for NHS Greater Glasgow and Clyde by:

Professionals drawing up PGD/Authors	
<p>*Name: Sarah Marshall</p>  <p>Signature: Date: 03/07/2025</p>	<p>Designation: Specialist Pharmacist Public Health</p> <p>E-mail address: sarah.marshall4@ggc.scot.nhs.uk</p>
<p>Name: Tina McMichael</p>  <p>Signature: Date: 03/07/2025</p>	<p>Designation: Health Protection Nurse Specialist</p> <p>E-mail address: tina.mcmichael2@ggc.scot.nhs.uk</p>

Name: Iain Kennedy  Signature: Date: 03/07/2025	Designation: Consultant in Public Health E-mail address: Iain.kennedy@ggc.scot.nhs.uk
---	--

Approved on behalf of NHS Greater Glasgow and Clyde by ADTC Patient Group

Direction Sub Committee representatives:

Chair	Dr Craig Harrow	
Senior Pharmacist	Elaine Paton, Senior Prescribing Adviser	
Nurse Director Representative	Kevin McAuley, Lead Nurse North Sector	

Date approved:03/07/2025.....

Effective from: 01 July 2025

Expiry date: 30 June 2028

1. Clinical situation

1.1. Indication

Immunisation against *Neisseria meningitidis* groups A, C, W and Y.

1.2. Inclusion criteria

- Adolescents aged 13 years to 18 years in line with the Scottish childhood immunisation programme.

- Individuals with uncertain or incomplete immunisation status in accordance with the **vaccination of individuals with uncertain or incomplete immunisation status** flow chart.
- Individuals requiring vaccination for the prevention of secondary cases of Meningitis ACWY, following specific advice from NHS Board Health Protection Team and who have not been vaccinated with MenACWY conjugate vaccine in the last 12 months.
- Individuals of any age who are at increased risk of invasive meningococcal infection due to underlying medical conditions or medicinal treatment and are invited, or eligible in accordance with the recommendations given in The Green Book **Chapter 7** and **22** and/or in line with subsequent correspondence/publications from Scottish Government.
- Individuals who have received a haematopoietic stem cell transplant or CAR-T therapy and who require revaccination, in accordance with the **Scottish Haematology Society Revaccination Schedule**.

Valid consent has been given to receive the vaccine.

1.3. Exclusion criteria

Individuals who:

- have had a confirmed anaphylactic reaction to a previous dose of meningococcal ACWY conjugate vaccine.
- have previously received MenACWY conjugate vaccine from 10 years of age and are due to be called for their routine vaccination offer in line with the national programme, with the exception of contacts of confirmed invasive meningococcal disease due to serogroups A, C, W or Y or those individuals

requiring revaccination in accordance with the Scottish Haematology Society Revaccination Schedule.

- have confirmed anaphylactic reaction to any constituent or excipient of the vaccine including meningococcal polysaccharide, diphtheria toxoid or the CRM197 carrier protein (Menveo®) or tetanus toxoid (Nimenrix® and MenQuadfi®). Practitioners must check the marketing authorisation holder's SmPC for details of vaccine components.
- have a history of severe reaction (i.e. anaphylactic reaction) to latex where vaccine is not latex free including syringe, tip and plunger.
- require vaccination for the purpose of travel (see separate travel PGD).
- are suffering from acute severe febrile illness (the presence of a minor illness without fever or systemic upset is not a contraindication for immunisation).

1.4. Cautions/need for further advice/circumstances when further advice should be sought from a doctor

The Green Book advises that there are very few individuals who cannot receive Meningococcal ACWY vaccine. Where there is doubt, rather than withholding vaccination, appropriate advice should be sought from the relevant specialist, or from the local immunisation or health protection team.

The presence of a neurological condition is not a contraindication to immunisation but if there is evidence of current neurological deterioration, deferral of vaccination may be considered, to avoid incorrect attribution of any change in the underlying condition. The risk of such deferral should be balanced against the risk of the preventable infection, and vaccination should be promptly given once the diagnosis and/or the expected course of the condition becomes clear.

Co-administration with other vaccines

Meningococcal ACWY conjugate vaccine can be given at the same time as other vaccines such as pneumococcal, measles, mumps and rubella (MMR), diphtheria, tetanus, pertussis, polio, Hib and HPV. Where applicable, an interval of at least 4 weeks should be observed between Hib/MenC and MenACWY vaccination, to further boost immune response to the MenC component.

The vaccines should be given at a separate site, preferably a separate limb. If given in the same limb, they should be given at least 2.5cm apart. The site at which each vaccine was given should be noted in the individual's records.

Syncope

Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.

Pregnancy and breastfeeding

Meningococcal vaccines may be given to pregnant women when clinically indicated. There is no evidence of risk from vaccinating pregnant women or those who are breast-feeding with inactivated virus or bacterial vaccines or toxoids.

1.5 Action if excluded

Specialist advice must be sought on the vaccine and circumstances under which it could be given. Immunisation using a patient specific direction may be indicated. The risk to the individual of not being immunised must be taken into account.

Document the reason for exclusion and any action taken in accordance with local procedures.

Individuals who have received MenACWY conjugate vaccine over 1 year of age and in the last 12 months do not require a further dose of MenACWY conjugate vaccine when diagnosed at risk.

Inform or refer to the clinician in charge.

Temporary Exclusion

In case of postponement due to acute severe febrile illness, advise when the individual can be vaccinated and ensure another appointment is arranged.

1.6. Action if patient declines

Advise the individual about the protective effects of the vaccine, the risks of infection and potential complications of disease.

Advise how future immunisation may be accessed if they subsequently decide to receive the vaccine.

Document advice given and decision reached.

Inform or refer to the clinician in charge.

2. Description of treatment

2.1. Name of medicine/form/strength

Meningococcal ACWY conjugate vaccine.

MenQuadfi® solution for injection

Menveo® powder and solution for solution for injection.

Nimenrix® powder and solvent for solution for injection in pre-filled syringe.

2.2. Route of administration

MenACWY vaccines should be administered by intramuscular (IM) injection preferably into the deltoid area of the upper arm. Where administration into the deltoid is not possible the anterolateral thigh can be considered. This is to reduce the risk of localised reactions, which are more common with subcutaneous injection. However, for individuals with a bleeding disorder, vaccines should be given by deep subcutaneous injection to reduce the risk of bleeding. Administration by deep subcutaneous injection to individuals with a bleeding disorder is off-label administration in line with advice in **Chapter 4** of the Green Book.

Where reconstitution is required, this must be done in accordance with the manufacturers' instructions prior to administration.

The vaccine should be visually inspected for particulate matter and discoloration prior to administration. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.

For vaccines which require reconstitution, it is recommended that the vaccine be administered immediately after reconstitution, to minimize loss of potency. Discard reconstituted vaccine if it is not used within 8 hours.

2.3. Dosage

0.5ml.

2.4. Frequency

Individuals with underlying medical conditions which puts them at risk of invasive meningococcal infection due to underlying medical conditions or medicinal treatment

Individuals first diagnosed or presenting under 1 year of age, with asplenia, splenic dysfunction or complement disorders, should receive:

- 2 primary doses of MenACWY vaccine at least 4 weeks apart during their first year, and
- one booster dose of MenACWY vaccine after the first birthday.

Where possible, the course should be completed with the same brand of MenACWY vaccine. However, vaccination should not be delayed and any of the licensed vaccines may be used.

Individuals first diagnosed or presenting over 1 year of age, with asplenia, splenic dysfunction or complement disorders, require a single dose of MenACWY vaccine on presentation, at least 4 weeks after vaccination with Hib/MenC, as applicable.

Refer to Green Book Chapter 7 for a practical schedule for immunising individuals with asplenia, splenic dysfunction or complement disorders, which takes into account the other vaccines required by these individuals.

Adolescents aged 13 years to 18 years in line with the Scottish childhood immunisation programme

Single dose.

Prevention of secondary cases of Meningococcal ACWY disease

Vaccination for the prevention of secondary cases of Meningococcal ACWY disease should be in accordance with recommendations from the local Public Health Protection Team and informed by the Public Health England [Guidance for Public Health Management of Meningococcal Disease in the UK](#).

Revaccination of individuals who have received a haemopoietic stem cell transplant

In accordance with the schedule recommended by the Scottish Haematology Society [Revaccination of patients following haematopoietic stem cell transplant or CAR-T treatment](#)

2.5. Duration of treatment

See frequency section.

2.6. Maximum or minimum treatment period

See frequency section.

2.7. Quantity to supply/administer

See frequency section.

2.8. ▼ black triangle medicines

Yes – MenQuadfi® is subject to additional monitoring and is designated as ▼

Healthcare professionals and individuals/carers should report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on <http://www.mhra.gov.uk/yellowcard>.

2.9. Legal category

Prescription only medicine (POM).

2.10. Is the use outwith the SmPC?

Administration by deep subcutaneous injection to individuals with a bleeding disorder is off-label administration in line with advice in Green Book, **Chapter 4**.

Menveo® is off-label for children under 2 years of age, as is MenQuadfi® for children under 12 months.

Nimenrix® is licensed from 6 weeks of age for a schedule with a 2 month interval between doses, but a one month interval is in accordance with the advice in **Chapter 22** of the Green Book.

All vaccines are recommended in accordance with the advice in **Chapter 22** of the Green Book.

Where possible, administer a vaccine licensed for the age of the individual. If no licensed vaccine is available, then an alternative vaccine may be given off-label to avoid undue delay.

Revaccination of individuals following haematopoietic stem cell transplant of CAR-T treatment is considered off-label but is in accordance with the **Scottish Haematology Society schedule**.

Vaccine should be stored according to the conditions detailed below. However, in the event of an inadvertent or unavoidable deviation of these conditions refer to NHS Board guidance on storage and handling of vaccines or National Vaccine Incident Guidance. Where vaccine is assessed in accordance with these guidelines as appropriate for continued use, administration under this PGD is allowed.

Where a vaccine is recommended off-label, consider, as part of the consent process, informing the individual, parent or carer that the vaccine is being offered in accordance with national guidance but that this is outside of the product licence.

2.11. Storage requirements

Vaccine should be stored at a temperature of +2° to +8°C.

Store in the original packaging to protect from light.

Do not freeze.

After reconstitution of Menveo® and Nimenrix®, the vaccine should be used immediately. However, stability after reconstitution has been demonstrated for 8 hours below 25°C (below 30°C for Nimenrix®). Discard any reconstituted vaccine not used within 8 hours.

NHS Board guidance on storage and handling of vaccines should be observed.

In the event of an inadvertent or unavoidable deviation of these conditions, vaccine that has been stored outside the conditions stated above should be quarantined and risk assessed for suitability of continued off-label use or appropriate disposal. See National Vaccine Incident Guidance.

2.12. Additional information

Minor illnesses without fever or systemic upset are not valid reasons to postpone immunisation. If an individual is acutely unwell, immunisation may be postponed until they have fully recovered.

The immunogenicity of the vaccine could be reduced in immunosuppressed individuals. However, vaccination should proceed in accordance with national recommendations.

Where possible, vaccines should be administered 2 weeks before immunosuppressive treatment begins, before immunosuppression occurs, or deferred until an improvement in immunity is seen.

Medical conditions such as coeliac disease, sickle cell disease and other haemoglobinopathies may be accompanied by functional hyposplenism. However, hyposplenism in coeliac disease is uncommon in children, and the prevalence

correlates with the duration of exposure to gluten. Therefore, individuals diagnosed with coeliac disease early in life and well managed are unlikely to require additional MenACWY vaccine. Only those with known splenic dysfunction should be vaccinated in accordance with this PGD.

Individuals receiving complement inhibitor therapy (such as eculizumab or ravulizumab) are at heightened risk of meningococcal infection and should be vaccinated with both MenACWY and MenB vaccines (see MenB PGD), ideally at least two weeks prior to commencement of therapy.

Impact of changes to the childhood immunisation programme from 1 July 2025 and discontinuation of Menitorix® (Hib/MenC)

Note that Hib/MenC will not be routinely offered to children at 1 year of age after 1 July 2025, with a date of birth on or after 1 July 2024. The Hib/MenC vaccine is no longer expected to be in circulation beyond April 2026 and may be offered to children born on or before 30 June 2024, until all supplies of the Hib/MenC vaccine have been exhausted. Practitioners should remain vigilant to the possibility that a young child requiring MenACWY for outbreak purposes may remain eligible for Hib/MenC. Where appropriate, advise the parent or legal guardian that a minimum 4 week gap is preferable before the Hib/MenC dose is given.

Individuals who require vaccination for the prevention of secondary cases of meningococcal serotype C, following assessment by the Health Protection Team, following an outbreak of invasive meningococcal disease, may be vaccinated with a licensed MenACWY conjugate vaccine in place of Menitorix®.

3. Adverse reactions

3.1. Warnings including possible adverse reactions and management of these

Menveo®

The most common adverse reactions observed after administration of Menveo® vaccine are drowsiness, malaise, headache, nausea, irritability and injection site pain, erythema and induration.

Fever, chills, nausea, vomiting, diarrhoea, eating disorders, myalgia, arthralgia and rash are also listed as common side effects.

Nimenrix®

The most common adverse reactions observed after administration of Nimenrix® vaccine are drowsiness, fatigue, headache, loss of appetite, irritability, fever and injection site pain, erythema and induration.

Gastro-intestinal symptoms (including nausea, vomiting and diarrhoea) and injection site haematoma are also listed as common side effects.

MenQuadfi®

The most common adverse reactions observed after administration of MenQuadfi® vaccine are malaise, headache, myalgia and injection site pain. Fever and injection site induration and erythema are also listed as common side effects.

For full details/information on possible side effects, refer to the marketing authorisation holder's SmPC.

As with all vaccines there is a very small possibility of anaphylaxis and facilities for its management must be available.

In the event of severe adverse reaction individual should be advised to seek medical advice.

3.2. Reporting procedure for adverse reactions

Healthcare professionals and individuals/carers should report all suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on <http://www.mhra.gov.uk/yellowcard>

Any adverse reaction to a vaccine should be documented in accordance with locally agreed procedures in the individual's record and the individual's GP should be informed.

3.3. Advice to patient or carer including written information

Written information to be given to individuals:

- Provide manufacturer's consumer information leaflet/patient information leaflet (PIL) provided with the vaccine.
- Supply immunisation promotional material as appropriate.

Individual advice/follow-up treatment:

- Inform the individual/carers of possible side effects and their management.
- The individual should be advised to seek medical advice in the event of a severe adverse reaction.
- Menveo®, Nimenrix® or MenQuadfi® will only confer protection against *Neisseria meningitidis* group A, C, W and Y. The vaccine will not protect against any other *Neisseria meningitidis* groups. Individuals should continue to

seek prompt medical attention at the first signs of possible meningitis or septicaemia.

- Inform the individual that they can report suspected adverse reactions to the MHRA using the Yellow Card reporting scheme on:
<http://www.mhra.gov.uk/yellowcard>
- When administration is postponed advise the individual how future vaccination may be accessed.
- When applicable, advise individual/parent/carer when the subsequent dose is due.

3.4. Observation following vaccination

As syncope (fainting) can occur following vaccination, all vaccinees should either be driven by someone else or should not drive for 15 minutes after vaccination.

Following immunisation, patients remain under observation in line with NHS board policy.

3.5. Follow up

Not applicable.

3.6. Additional facilities

A protocol for the management of anaphylaxis and an anaphylaxis pack must always be available whenever vaccines are given. Immediate treatment should include early treatment with intramuscular adrenaline, with an early call for help and further IM adrenaline every 5 minutes.

The health professionals overseeing the immunisation service must be trained to recognise an anaphylactic reaction and be familiar with techniques for resuscitation of a patient with anaphylaxis.

4. Characteristics of staff authorised under the PGD

4.1. Professional qualifications

The following classes of registered healthcare practitioners are permitted to administer this vaccine:

- nurses and midwives currently registered with the Nursing and Midwifery Council (NMC)
- pharmacists currently registered with the General Pharmaceutical Council (GPhC)
- pharmacy technicians currently registered with the General Pharmaceutical Council (GPhC)
- chiropodists/podiatrists, dieticians, occupational therapists, orthoptists, orthotists/prosthetists, paramedics, physiotherapists, radiographers and speech and language therapists currently registered with the Health and Care Professions Council (HCPC)
- dental hygienists and dental therapists registered with the General Dental Council
- optometrists registered with the General Optical Council.

4.2. Specialist competencies or qualifications

Persons must only work under this PGD where they are competent to do so.

All persons operating this PGD:

- must be authorised by name by their employer as an approved person under the current terms of this PGD before working to it.

- must be familiar with the vaccine product and alert to changes in the manufacturer's product information/summary of product information.
- must be competent to undertake immunisation and to discuss issues related to immunisation to assess patients for vaccination and obtain consent.
- must be competent in the correct storage of vaccines and management of the cold chain if receiving, responsible for, or handling the vaccine.
- must be competent in the recognition and management of anaphylaxis or under the supervision of persons able to respond appropriately to immediate adverse reactions.
- must have access to the PGD and associated online resources.
- should fulfil any additional requirements defined by local policy.

Employer

The employer is responsible for ensuring that persons have the required knowledge and skills to safely deliver the activity they are employed to provide under this PGD.

As a minimum, competence requirements stipulated in the PGD must be adhered to.

4.3. Continuing education and training

All practitioners operating under the PGD are responsible for ensuring they remain up to date with the use of vaccines included. If any training needs are identified these should be discussed with the individuals in the organisation responsible for authorising individuals to act under this PGD.

5. Audit trail

Record the following information:

- valid informed consent was given
- name of individual, address, date of birth and GP with whom the individual is registered if possible
- name of person that undertook assessment of individual's clinical suitability and subsequently administered the vaccine
- name and brand of vaccine
- date of administration
- dose, form and route of administration of vaccine
- batch number
- where possible expiry date
- anatomical site of vaccination
- advice given, including advice given if excluded or declines immunisation
- details of any adverse drug reactions and actions taken
- administered under PGD

Records should be kept in line with local procedures

Local policy should be followed to encourage information sharing with the individual's General Practice

All records should be clear, legible and contemporaneous and in an easily retrievable format.

6. Additional references

Practitioners operating the PGD must be familiar with:

- **Immunisation against Infectious Disease [Green Book].**
- **Immunisation against Infectious Disease [Green Book] chapter 22 Meningococcal.**
- **Immunisation against Infectious Disease (Green Book) chapter 7, Immunisation of individuals with underlying medical conditions.**
- **Scottish Haematology Society advice on the revaccination of patients following haematopoietic stem cell transplant or CAR-T treatment**
- **Guidance for Public Health Management of Meningococcal Disease in the UK.**
- Current edition of **British National Formulary (BNF)** and **BNF for children.**
- **Marketing authorisation holder's Summary of Product Characteristics.**
- All relevant Scottish Government advice including the relevant CMO letter(s).
- **Professional Guidance on the Administration of Medicines in Healthcare Settings 2019.**
- **Professional Guidance on the Safe and Secure Handling of Medicines**
- **Educational resources for registered professionals produced by National Education for Scotland**

7. PGD for administration of Meningococcal ACWY conjugate vaccine V7.0 (valid from 01 July 2025 and expires 30 June 2028): authorisation

Practitioner

This PGD does not remove professional obligations and accountability. It is the responsibility of each professional to practice within the bounds of their own competence and in accordance with their Code of Professional Conduct and to ensure familiarity with the marketing authorisation holder's summary of product characteristics for all vaccines administered in accordance with this PGD.

By signing this Patient Group Direction, you are indicating that you agree to its contents and that you will work within it.

I agree to administer Meningococcal ACWY conjugate vaccine only in accordance with this PGD.

Name of professional	Signature	Date

Authorising manager

I confirm that the practitioners named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of **NHS Greater Glasgow & Clyde** for the above-named health care professionals who have signed the PGD to work under it.

Lead clinician for the service area:

Name

Signature

Date

Authorised staff should be provided with an individual copy of the clinical content of the PGD and a photocopy of the document showing their authorisation.

This authorisation sheet should be retained to serve as a record of those practitioners authorised to work under this PGD.

8. Version history

Version	Date	Summary of changes
5.0	July 2020	<p>Version 5.0 produced (now branded as Public Health Scotland national specimen PGD).</p> <p>The following changes from version 4.0 of the PGD have been made:</p> <ul style="list-style-type: none"> • Use outwith SmPC section updated to recommend assessment following inadvertent or unavoidable deviation from recommended storage conditions. • Use outwith SmPC section updated to highlight administration by deep subcutaneous injection to individuals with a bleeding disorder is off-label administration in line with advice in Chapter 4 of 'The Green Book'. • Storage section updated to include additional information on action required following inadvertent or unavoidable deviation from recommended storage conditions. • References section updated.
6.0	1 June 2022	<ul style="list-style-type: none"> • Inclusion criteria expanded to include other patient groups out with the Scottish childhood immunisation programme. • Frequency section updated to include dosing information for the other patient groups out with the Scottish childhood immunisation programme. • Additional information section updated to include further information on individuals with asplenia, splenic dysfunction or complement disorders and individuals receiving complement inhibitor therapy. • This PGD has undergone minor rewording, layout, formatting changes for clarity and consistency with other PHS national specimen PGDs.
6.1	1 December 2022	<ul style="list-style-type: none"> • Additional information section updated with minor amendments for those individuals diagnosed with coeliac disease early in life and well managed and for individuals receiving complement inhibitor therapy.

Version	Date	Summary of changes
6.2	1 March 2024	<p>The following changes to version 6.1 of the PGD have been made:</p> <ul style="list-style-type: none"> • minor rewording, layout and formatting changes for clarity and consistency with other PHS PGDs • Inclusion criteria, frequency, is the use outwith the SmPC and additional reference sections updated to include reference to the Scottish Haematology Society schedule for the revaccination of individuals following haematopoietic stem cell transplant or CAR-T treatment. • Inclusion criteria amended to include individuals invited, or eligible in accordance with the recommendations in Green Book and/or in line with subsequent correspondence/publications from Scottish Government. • Observation following vaccination section updated to include advice on driving post-immunisation
6.3	31 May 2024	<p>The following changes to version 6.2 of the PGD have been made:</p> <ul style="list-style-type: none"> • Addition of MenQuadfi® to relevant sections • Typographical change to remove inclusion criteria relating to pneumococcal disease
7.0	01 July 2025	<p>The following changes to version 6.3 of the PGD have been made:</p> <ul style="list-style-type: none"> • Inclusion criteria updated in relation to individuals requiring vaccination for the prevention of secondary cases of Meningitis ACWY • Exclusion added in relation to those that have previously received MenACWY conjugate vaccine from 10 years of age • Exclusion section, latex allergy wording updated • Section 1.4 Coadministration with other vaccines updated to reflect interval guidance in relation to Hib/MenC and MenACWY vaccination

Version	Date	Summary of changes
		<ul style="list-style-type: none"> • Section 1.5 Action if excluded updated in relation to individuals who have received MenACWY conjugate vaccine over 1 year of age and in the last 12 months • Section 2.2 Route of Administration, subcutaneous off licence wording updated to align with Chapter 4 of the Green Book. • Section 2.4 Frequency for individuals with underlying medical conditions updated to reflect Green Book Chapter 7 guidance and changes to routine childhood immunisation programme from 01 July 2025 • Section 2.10. Is the use outwith the SmPC? Information added in relation to off-label use and consent process, consider, as part of the consent process • Section 2.12 Additional Information, information added on: vaccine administration in relation to commencement of immunosuppressive treatment • Changes to the childhood immunisation programme from 1 July 2025 and discontinuation of Menitorix® (Hib/MenC) • Section 3.3 Advice to patient or carer updated to include advice in relation to protection only conferred against groups A, C, W and Y • Section 4.1 updated to include pharmacy technicians